HUTCHMED DRC (HCM)
[Press Release] HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
[Press Release] HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak financial signals • Minimal market impact expected **Sentiment:** Neutral (50%) **Content type:** Financial